Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Phase 1/2 Recruiting
16 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
MK-3475-051
Phase 1/2 Recruiting
370 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Phase 1/2 Recruiting
980 enrolled
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/2 Recruiting
92 enrolled
A Study of TRK-950 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
49 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1/2 Recruiting
188 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Phase 1/2 Recruiting
180 enrolled
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
Phase 1/2 Recruiting
15 enrolled
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Phase 1/2 Recruiting
35 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
MK-3475-D20
Phase 1/2 Recruiting
176 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/2 Recruiting
266 enrolled
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Phase 1/2 Recruiting
336 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/2 Recruiting
135 enrolled
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Phase 1/2 Recruiting
30 enrolled
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Phase 1/2 Recruiting
188 enrolled
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Phase 1/2 Recruiting
200 enrolled
BrILliance
Phase 1/2 Recruiting
240 enrolled
DETERMINE
Phase 1/2 Recruiting
33 enrolled
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/2 Recruiting
42 enrolled
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/2 Recruiting
36 enrolled
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/2 Recruiting
350 enrolled
Tebentafusp-tebn With LDT in Metastatic UM
Phase 1/2 Recruiting
109 enrolled
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
862 enrolled
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/2 Recruiting
754 enrolled
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2 Recruiting
108 enrolled
RABBIT
Phase 1/2 Recruiting
30 enrolled
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Phase 1/2 Recruiting
50 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled
NG2 and DLL3 CAR-T Cells Targeting Melanoma
Phase 1/2 Recruiting
100 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
Combination Immunotherapy Targeting Melanoma
Phase 1/2 Recruiting
30 enrolled
AMT-253 in Patients With Advanced Solid Tumours
Phase 1/2 Recruiting
96 enrolled
Agni-01
Phase 1/2 Recruiting
52 enrolled
A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/2 Recruiting
64 enrolled
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/2 Recruiting
117 enrolled
OH2 Injection in Solid Tumors
Phase 1/2 Recruiting
30 enrolled
OH2 Injection in Combination With HX008 for Melanoma.
Phase 1/2 Recruiting
60 enrolled
START-001
Phase 1/2 Recruiting
365 enrolled